News

Invitation to presentation of Q3 2016 results

Biotec Pharmacon presents its report for the third quarter 2016 on Wednesday, 26 October. The presentation will be given by CEO Svein Lien, MD ArcticZymes Jethro Holder and VP Marketing Woulgan Stuart Devine. 

The presentation starts at 08:30 am and will be in English.

Venue: Hotell Continental, Stortingsgata 24, Oslo.

The presentation can also be followed as a live webcast from Hegnar TV and it will be possible to post questions through the webcast console at the end of the presentation.

You can find the webcast continue reading »

ArcticZymes launches its first Polymerase product and has been granted patent protection on its heat-labile Salt Active Nuclease in the USA

(Tromsø, 30 September 2016) Biotec Pharmacon ASA’s (”Biotec”, OSE: BIOTEC) subsidiary ArcticZymes has today launched its first DNA polymerase product onto the market. Also, it has received patent protection for its heat-labile Salt Active Nucleases (SAN) in the USA.

 ArcticZymes launches its first DNA polymerase as part of a new portfolio offering. The IsoPolTM DNA Polymerase is a novel isothermal polymerase with distinct properties compared to other enzymes on the market. For ArcticZymes, the isothermal polymerase portfolio represents both commercial potential … continue reading »

Confirmation of German reimbursement in 2nd region and additional questions from UK Drug Tariff

(Tromsø, 19 September 2016) Biotec Pharmacon ASA (”Biotec”, OSE: BIOTEC) has passed  another important milestone for the German market with confirmation of Woulgan® being reimbursed by a leading Statutory Health Insurance fund (krankenkasse) in a 2nd major region.

 – We are very pleased with this development as it gives us an excellent platform to promote Woulgan® in Germany. Confirmation that Woulgan® will be reimbursed by this “krankenkasse” in two large, well-populated territories is an encouraging start. Biotec, together with its German … continue reading »

Invitation to presentation of Q2 2016 results

Biotec Pharmacon presents its report for the second quarter 2016 on Wednesday, 17 August The presentation will be given by CEO Svein Lien and VP Marketing Woulgan Stuart Devine.

The presentation starts at 08:30 am and will be in English.

Venue: Hotell Continental, Stortingsgata 24, Oslo.

The presentation can also be followed as a live webcast from Hegnar TV on www.biotec.no, and it will be possible to post questions through the webcast console at the end of the presentation.

You can find the … continue reading »

Market update – Commercialization Woulgan

(Tromsø, 30. June 2016) Biotec Pharmacon ASA (“Biotec”, OSE: BIOTEC) is
continuing to focus on their short and medium term goals presented at  the
Capital Markets Day in February and the Q1 presentation in April.
This week, Biotec will file the 510K application for the important US market.
The process normally takes 6-9 months and expects feedback from the authorities
late in 2016 or early 2017. Registering Woulgan® in this way will form the
foundation for the commercially valuable registration and reimbursement work to
follow. The company … continue reading »

Enters into German distribution agreement for Woulgan®

(Tromsø, 13 June 2016) Biotec Pharmacon ASA has entered into a distribution agreement for Woulgan® with the German distributor Rogg Verbandstoffe GmbH (Rogg).

-Biotec is pleased to announce Rogg as the first German distribution partner of Woulgan®. The agreement is in line the Biotec’s outlook to secure one or more distribution agreement in Germany during 2016. With its 20 sales reps, Rogg is well positioned to succeed with Woulgan® in their focused segments and we look forward to start the … continue reading »

Biotec cleared in arbitration matter

(Tromsø, 13. June 2016) Biotec Pharmacon ASA has today received the decision by the arbitration court related to the Company’s nutrition business brought up by company Sana Pharma AS.

The decision by the arbitration court clears Biotec from all matters sought and the plaintiff will pay the litigation cost for both parties.

-We are very glad for this positive decision by the arbitration court and to put this matter behind us. Despite this ongoing matter we have continued a good working … continue reading »

Innkalling til ordinær generalforsamling i Biotec Pharmacon ASA

Den ordinære generalforsamlingen i Biotec Pharmacon ASA avholdes onsdag den 11.mai 2016, kl 16:00 i SIVA Innovasjonssenter (Forskningsparken), Sykehusveien 23, Tromsø.

Skriftlig innkalling til generalforsamlingen er postlagt til selskapets aksjonærer som var registrert i VPS per 13. april 2016. Årsrapporten for 2015 er publisert i seperat børsmelding og den er også lagt ut på selskapets
hjemmeside www.biotec.no/investors/reports-and-presentations.

På selskapets hjemmeside er følgende dokumenter vedrørende generalforsamlingen tilgjengelig:
· Innkalling til generalforsamling 11. mai 2016
· Innstilling valgkomite 2016

For ytterligere informasjon, kontakt:

Børge Sørvoll
CFO
+47 952 90187 continue reading »